Cash Flow Statement
Quarterly Data

The cash flow statement provides information about a company cash receipts and cash payments during an accounting period, showing how these cash flows link the ending cash balance to the beginning balance shown on the company balance sheet.

The cash flow statement consists of three parts: cash flows provided by (used in) operating activities, cash flows provided by (used in) investing activities, and cash flows provided by (used in) financing activities.

Celgene Corp., consolidated cash flow statement (quarterly data)

US$ in millions

3 months ended:	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019	Dec 31, 2018	Sep 30, 2018	Jun 30, 2018	Mar 31, 2018	Dec 31, 2017	Sep 30, 2017	Jun 30, 2017	Mar 31, 2017	Dec 31, 2016	Sep 30, 2016	Jun 30, 2016	Mar 31, 2016	Dec 31, 2015	Sep 30, 2015	Jun 30, 2015	Mar 31, 2015	Dec 31, 2014	Sep 30, 2014	Jun 30, 2014	Mar 31, 2014
Net income (loss)	1,691)	1,571)	1,545)	1,073)	1,082)	1,045)	846)	(81)	988)	1,101)	932)	429)	171)	598)	801)	561)	(34)	356)	719)	614)	509)	598)	280)
Depreciation	48)	47)	47)	41)	40)	41)	38)	34)	34)	34)	32)	32)	31)	29)	29)	28)	29)	30)	28)	26)	26)	27)	26)
Amortization	123)	111)	110)	129)	129)	129)	88)	82)	81)	90)	84)	408)	139)	211)	114)	118)	88)	68)	69)	66)	198)	67)	72)
Impairment charges	—)	—)	—)	1)	3)	27)	—)	1,628)	1)	50)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)
Deferred income taxes	59)	(38)	(41)	42)	33)	9)	(52)	(1,135)	(9)	(106)	(80)	(87)	(90)	(123)	(43)	380)	(161)	(146)	(107)	(24)	(68)	(101)	(80)
Change in value of contingent consideration and success payments	(1)	(47)	30)	(55)	97)	7)	(30)	(1,425)	49)	(13)	39)	9)	23)	(44)	33)	9)	(7)	(29)	19)	38)	2)	1)	9)
Gain on sale of business	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	(38)	—)	—)	—)	—)	—)	—)	—)	—)
Net (gain) loss on sales of debt securities available-for-sale	—)	—)	—)	—)	—)	—)	18)	(43)	(3)	(15)	—)	—)	—)	(7)	—)	1)	2)	(86)	—)	1)	1)	3)	—)
Fair value adjustments on equity investments	222)	147)	(269)	513)	124)	5)	(959)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)
Share-based compensation expense	176)	225)	257)	190)	239)	284)	208)	162)	159)	170)	153)	155)	148)	158)	147)	150)	150)	148)	129)	128)	111)	103)	104)
Share-based employee benefit plan expense	—)	—)	—)	—)	13)	11)	9)	(1)	13)	12)	10)	12)	9)	11)	9)	11)	7)	9)	8)	11)	12)	10)	7)
Derivative instruments	—)	23)	8)	14)	(19)	30)	(22)	58)	(46)	53)	7)	(24)	208)	(36)	21)	8)	(36)	3)	(7)	(49)	(11)	(18)	6)
Other, net	(36)	(40)	2)	(1)	(4)	(12)	2)	(6)	28)	(46)	—)	(1)	(11)	4)	(2)	1)	22)	(4)	1)	(10)	1)	(3)	(1)
Accounts receivable	54)	(114)	(271)	47)	(68)	(110)	(47)	(97)	(64)	(92)	17)	(79)	(63)	(104)	23)	(159)	(5)	(81)	(60)	(120)	16)	(52)	(10)
Inventory	12)	(21)	16)	51)	45)	(20)	6)	(5)	(5)	(22)	(10)	7)	(17)	(20)	(26)	(24)	(8)	(27)	7)	(23)	(15)	(12)	(7)
Other operating assets	(171)	21)	50)	319)	(51)	(152)	(171)	212)	(101)	(213)	29)	(43)	37)	62)	39)	(309)	29)	(20)	(26)	(3)	19)	7)	30)
Accounts payable and other operating liabilities	13)	99)	(28)	356)	78)	75)	(219)	245)	(191)	584)	(365)	455)	109)	185)	(130)	277)	179)	18)	59)	178)	94)	(132)	112)
Income tax payable	(4)	234)	35)	(371)	156)	(168)	(10)	2,064)	132)	29)	4)	84)	14)	16)	(3)	17)	11)	17)	16)	11)	3)	14)	11)
Payment of contingent consideration	—)	(16)	(13)	—)	—)	—)	(22)	—)	—)	—)	—)	(9)	—)	—)	—)	—)	—)	—)	—)	(9)	—)	—)	(5)
Deferred revenue	(14)	(35)	(2)	(6)	27)	28)	(8)	(3)	22)	—)	1)	(5)	15)	(5)	2)	(12)	18)	29)	2)	(3)	3)	4)	4)
Change in current assets and liabilities, excluding the effect of acquisitions and disposals	(110)	168)	(213)	396)	187)	(347)	(471)	2,416)	(207)	286)	(324)	411)	95)	135)	(95)	(209)	225)	(65)	(2)	30)	121)	(171)	135)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities	481)	596)	(69)	1,270)	842)	184)	(1,171)	1,770)	100)	515)	(79)	914)	551)	338)	174)	497)	319)	(72)	138)	219)	392)	(82)	277)
Net cash provided by (used in) operating activities	2,172)	2,167)	1,476)	2,343)	1,924)	1,229)	(325)	1,689)	1,088)	1,616)	853)	1,343)	723)	936)	975)	1,058)	285)	284)	857)	833)	901)	516)	557)
Proceeds from sales of debt securities available-for-sale	602)	113)	261)	5)	143)	37)	3,203)	2,678)	1,233)	1,791)	266)	91)	114)	114)	314)	138)	2,082)	500)	1,080)	514)	518)	556)	588)
Purchases of debt securities available-for-sale	(3)	(62)	(428)	(435)	(130)	(48)	(62)	(1,762)	(3,305)	(1,620)	(1,791)	(720)	(128)	(147)	(285)	(190)	(572)	(448)	(679)	(524)	(581)	(790)	(767)
Capital expenditures	(68)	(60)	(69)	(98)	(64)	(80)	(88)	(103)	(44)	(70)	(62)	(66)	(67)	(44)	(60)	(141)	(51)	(53)	(42)	(49)	(40)	(37)	(25)
Proceeds from sales of equity investment securities	17)	1)	2)	—)	41)	—)	55)	(12)	5)	27)	—)	2)	2)	11)	—)	7)	—)	78)	7)	—)	—)	—)	—)
Purchases of equity investment securities	(11)	(35)	(61)	(73)	(21)	(37)	(118)	297)	(236)	(79)	(77)	(10)	(33)	(10)	(79)	(56)	(16)	(173)	(28)	(9)	(36)	(5)	(18)
Payments for acquisition of businesses, net of cash acquired	—)	—)	—)	—)	—)	—)	(8,648)	—)	—)	—)	—)	—)	—)	—)	—)	(116)	(7,579)	—)	—)	—)	—)	(710)	—)
Payment for acquisition of intangible asset	(400)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)
Other	—)	—)	—)	—)	—)	—)	—)	—)	(27)	(4)	4)	—)	(1)	—)	—)	(3)	(2)	(3)	—)	(4)	(21)	—)	1)
Net cash (used in) provided by investing activities	137)	(43)	(295)	(601)	(31)	(128)	(5,658)	1,098)	(2,374)	45)	(1,660)	(704)	(112)	(75)	(110)	(361)	(6,138)	(98)	338)	(73)	(159)	(986)	(220)
Payment for treasury shares	—)	—)	—)	—)	—)	(3,396)	(2,700)	(2,908)	(114)	(518)	(293)	(134)	(320)	(296)	(1,410)	(683)	(577)	(985)	(1,013)	(541)	(252)	(614)	(1,569)
Proceeds from short-term borrowing	—)	—)	—)	—)	780)	3,114)	1,815)	—)	—)	—)	—)	100)	—)	—)	—)	3,881)	1,260)	881)	90)	130)	202)	775)	1,460)
Principal repayments on short-term borrowing	—)	—)	—)	1)	(1,776)	(2,119)	(1,815)	—)	—)	—)	—)	(100)	—)	—)	—)	(4,582)	(1,421)	(20)	(190)	(130)	(294)	(1,453)	(1,135)
Proceeds from issuance of long-term debt	—)	—)	—)	—)	—)	—)	4,452)	2,972)	496)	—)	—)	—)	—)	—)	—)	—)	7,913)	—)	—)	—)	—)	2,471)	—)
Principal repayments on current portion of long-term debt	—)	(500)	—)	—)	—)	—)	—)	(1,404)	(500)	—)	—)	—)	—)	—)	—)	(514)	—)	—)	—)	—)	—)	—)	—)
Net proceeds (payments) from common equity put options	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	2)	3)	3)	(19)	4)	1)	5)	5)	1)	4)	1)
Payment of contingent consideration	—)	(24)	(58)	—)	—)	—)	(40)	—)	—)	—)	—)	(41)	—)	—)	—)	—)	—)	—)	—)	(11)	—)	—)	(15)
Net proceeds from share-based compensation arrangements	102)	177)	84)	15)	83)	2)	44)	48)	250)	203)	184)	168)	115)	14)	62)	48)	100)	(10)	114)	92)	111)	35)	59)
Excess tax benefit from share-based compensation arrangements	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	59)	48)	57)	25)	57)	70)	90)	85)	104)	56)	60)	30)
Net cash provided by (used in) financing activities	102)	(347)	26)	16)	(913)	(2,399)	1,756)	(1,292)	132)	(315)	(109)	53)	(156)	(223)	(1,320)	(1,813)	7,349)	(43)	(908)	(352)	(176)	1,279)	(1,169)
Effect of currency rate changes on cash and cash equivalents	(21)	4)	(8)	(4)	(3)	(18)	33)	7)	5)	41)	19)	(44)	5)	(20)	20)	(20)	(10)	20)	(40)	(29)	(43)	15)	(6)
Net increase (decrease) in cash and cash equivalents	2,390)	1,781)	1,199)	1,754)	977)	(1,316)	(4,194)	1,502)	(1,149)	1,387)	(897)	647)	459)	618)	(435)	(1,136)	1,486)	163)	246)	379)	523)	823)	(838)

Net income (loss): The net income showed a generally positive trend with fluctuations over the periods. It increased from 280 million USD in March 2014 to a peak of 1691 million USD by September 2019. Several quarters showed declines, including notable losses in September 2015 (-34 million USD) and December 2017 (-81 million USD), but the overall direction was upward towards the end of the period.
Depreciation: Depreciation expenses steadily increased from 26 million USD in early 2014 to 48 million USD by late 2019, reflecting a gradual growth in capital asset bases or changes in asset utilization.
Amortization: Amortization displayed considerable volatility, with large spikes such as 198 million USD in September 2014 and 408 million USD in December 2016. Despite fluctuations, it averaged higher levels in the later periods, suggesting increased intangible asset amortization.
Impairment charges: Impairment charges were sporadic and notably significant in June 2017 with 1628 million USD, indicating a major write-down during this quarter. Other impairment amounts were minor or absent.
Deferred income taxes: This item fluctuated between positive and negative values, with a marked extreme negative value of -1135 million USD in December 2017, implying substantial tax adjustments or losses deferred during that quarter.
Change in value of contingent consideration and success payments: The values were inconsistent with both positive and negative swings, including an extreme negative value of -1425 million USD in December 2017, likely associated with settlement or valuation changes of contingent liabilities.
Gain on sale of business: There was a recorded loss of -38 million USD in March 2016, with no other significant entries, implying a single event impacting earnings that quarter.
Net (gain) loss on sales of debt securities available-for-sale: The data shows small gains and losses across periods without a clear trend, indicating routine investment portfolio adjustments.
Fair value adjustments on equity investments: Significant negative adjustment (-959 million USD) appeared in June 2017 followed by positive adjustments reaching 513 million USD in December 2018, highlighting substantial valuation changes in equity investments.
Share-based compensation expense: This expense generally increased from 104 million USD in early 2014 to a peak of 284 million USD in June 2018, then declined but remained elevated, reflecting growing employee compensation through equity grants.
Accounts receivable: Accounts receivable changes showed high variability, with large negative impacts especially in March 2019 (-271 million USD), suggesting fluctuations in collections or sales timing impacting working capital.
Inventory: Inventory changes were mostly negative or minor positive amounts, showing occasional buildup or reduction but without a sustained trend.
Other operating assets: This category exhibited significant volatility; notably large negative impacts (-309 million USD in December 2014 and -213 million USD in June 2017) alternated with positive swings, indicating changes in miscellaneous operational asset accounts.
Accounts payable and other operating liabilities: The figures showed high variability with large positive and negative swings, highlighting fluctuating obligations. For instance, large negative cash effect of -365 million USD in March 2016 was offset by a strong positive movement of 584 million USD the following quarter.
Income tax payable: This liability account fluctuated largely, with a marked increase to 2064 million USD in December 2017, signaling a significant tax position adjustment.
Deferred revenue: Deferred revenue showed small and inconsistent changes with no clear pattern, indicating stable contract liability management.
Net cash provided by (used in) operating activities: Operating cash flows were mostly positive and showed overall growth from 557 million USD in March 2014 to 2172 million USD by September 2019, with some intermittent dips, reflecting strong cash generation capability.
Net cash (used in) provided by investing activities: Investing activities mostly reflected cash use, with a few quarters showing positive net inflows (e.g., 338 million USD in March 2015 and 1098 million USD in December 2017). Large cash outflows were evident in quarters with acquisition activity, such as -6138 million USD in September 2015 and -5658 million USD in March 2018.
Net cash provided by (used in) financing activities: Financing cash flows fluctuated significantly, featuring both large inflows and outflows. Notable outgoing cash included -2908 million USD in December 2017 related to treasury shares buybacks, while several quarters recorded inflows from debt issuance and treasury transactions.
Capital expenditures: Capital expenditures generally ranged between 25 and 141 million USD per quarter, with no strong trend, indicating stable investment in property and equipment.
Overall cash and equivalents: Cash and cash equivalents showed periods of both increase and decrease. Particularly large decreases occurred in March 2018 (-4194 million USD) and June 2018 (-1316 million USD), while strong increases recurred toward late 2018 and 2019, ending with a 2390 million USD increase in September 2019, supporting liquidity growth.

Download chart

Celgene Corp. (NASDAQ:CELG)

Cash Flow Statement Quarterly Data

Cash Flow Statement
Quarterly Data